2-Pyrrolidone

2-Pyrrolidone

SCHEMBL6940458

NCCCN1CCCC1=O.O=C1CCCN1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 1/20 0.46
FKBP5 Q13451 1/20 0.40
CRBN Q96SW2 1/20 0.40
TSHR P16473 2/20 0.39
KDM4E B2RXH2 2/20 0.37
POLB P06746 2/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 5/20 0.37
MEN1 O00255 2/20 0.37
PKM P14618 1/20 0.37
PIK3CD O00329 1/20 0.37
ADRA1B P35368 5/20 0.36
ADRA1A P35348 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MALT1 Q9UDY8 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Pyrrolidone SCHEMBL17595381 0.91 OR51E2 (0.48) OR51E2FKBP5CRBNTSHRKDM4E
SCHEMBL56994 0.85 TSHR (0.50) TSHRPOLBKMT2AMEN1PKM
Ammonia Solution, Strong SCHEMBL1579461 0.84 TSHR (0.48) TSHRPOLBKMT2AMEN1PKM
Water SCHEMBL27492735 0.84 TSHR (0.48) TSHRPOLBKMT2AMEN1PKM
2-Pyrrolidone SCHEMBL2014976 0.82 ALOX5 (0.52) OR51E2FKBP5CRBNKDM4EGAA
SCHEMBL4401518 0.80 TSHR (0.48) TSHRPOLBKMT2AMEN1PKM
SCHEMBL1447146 0.80 TSHR (0.44) TSHRPOLBKMT2AMEN1PKM
2-Pyrrolidone SCHEMBL1746680 0.79 ALOX5 (0.49) OR51E2FKBP5CRBNKDM4EGAA
Hydrochloric Acid SCHEMBL4056528 0.79 TSHR (0.43) TSHRKMT2AMEN1PKMPIK3CD
SCHEMBL7933852 0.79 TSHR (0.47) TSHRPOLBKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1438991-A Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER CIMITED (US) 2003-08-27 CN disclosed
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 OR51E2 2999/4885FKBP5 914/4885CRBN 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.